In-depth research on therapeutic peptides including BPC-157, Semax, Selank, KPV, DSIP, and more. Explore mechanisms of action, clinical studies, dosing protocols, and safety profiles backed by published science.
MMP-1 and MMP-9 are zinc-dependent enzymes that UV radiation activates within hours of sun exposure, cleaving type I and type III collagen and accelerating dermal aging. Understanding TIMP regulators and copper peptide modulation reveals why some interventions reverse photoaging while others fail.
Matrikines are peptide fragments liberated from collagen, elastin, and laminin during extracellular matrix turnover. Unlike growth factors, they directly instruct fibroblasts to remodel tissue — making them a foundational target in dermal aging therapy.
Semax is a synthetic ACTH(4-7) analog that crosses the blood-brain barrier intranasally, engaging melanocortin receptors to upregulate BDNF and modulate dopaminergic tone in the prefrontal cortex.
SNAP-8 is a topical octapeptide that competitively inhibits the SNARE complex — the same molecular machinery blocked by botulinum toxin — offering a non-injectable approach to expression line attenuation.
SNAP-8 is an eight-amino-acid peptide modeled on the N-terminus of SNAP-25 that competitively interferes with SNARE complex assembly — offering a topical mechanism for softening expression lines distinct from botulinum toxin injection.
Delta sleep-inducing peptide (DSIP) is a nine-amino-acid neuropeptide that influences slow-wave sleep through GABAergic modulation and HPA-axis suppression — a mechanism profile distinct from benzodiazepines or melatonin.
Semax is a synthetic heptapeptide derived from ACTH(4-10) that dramatically upregulates BDNF expression in the hippocampus while modulating dopamine and serotonin systems — making it one of the most studied neuroprotective peptides in Russian clinical literature.
Semax is a synthetic ACTH(4-10) fragment developed in Russia that rapidly upregulates BDNF and modulates monoaminergic systems — a mechanism distinct from stimulants or racetams.
Tirzepatide is the first dual GIP/GLP-1 receptor agonist approved by the FDA, producing weight loss and glycemic improvements that exceed every prior incretin therapy in head-to-head trials.
MOTS-c is encoded in mitochondrial DNA and activates AMPK — the same metabolic sensor triggered by exercise. Research shows effects on insulin sensitivity, fat metabolism, and aging.